Intarcia boosts private cash with $1bn-plus Servier deal
This article was originally published in Scrip
For Intarcia Therapeutics, which wanted to retain 100% of the domestic rights to its once-yearly diabetes drug, Servier turned out to be the best possible partner to commercialize ITCA 650 in foreign markets given the French pharmaceutical firm's long-standing aversion to the US market.
You may also be interested in...
Intarcia announced $215m in new equity financing and revised its NDA submission timeline for the second time since it reported positive Phase III results for ITCA 650 versus Januvia in mid-2015.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.